"BEST PRICE" DISCOUNTS TO HMOs AND GPOs CONTINUE TO DECREASE
Executive Summary
"BEST PRICE" DISCOUNTS TO HMOs AND GPOs CONTINUE TO DECREASE, a General Accounting Office report released Aug. 5 finds. GAO calculated that 21% of HMO best prices on pharmaceuticals increased more than 30% between the first quarter of 1992 and the first quarter of 1993, compared with 18.5% over the previous 12 months. Among group purchasing organizations, 17.7% of best prices increased more than 30% from 1992 to 1993, versus 20.8% for the prior year.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth